Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neurotrope, Inc.NTRP · Entity 144906 | See Remarks | December 01, 2020 | December 03, 2020 |
| TAO Synergies Inc.SNPX · Entity 7482 | Director · President and CSO | December 16, 2022 | December 20, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neurotrope, Inc.
Report date December 01, 2020 · Filed December 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 1
1 source rowRow 1 · 2020-12-01 · Disposition to issuer · Disposed 29,688 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.00 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-01 · Disposition to issuer · Disposed 5,469 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-01 · Disposition to issuer · Disposed 124,274 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.62 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-01 · Disposition to issuer · Disposed 167,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-12-01 · Disposition to issuer · Disposed 150,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-12-01 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held.
F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
TAO Synergies Inc.
Report date December 16, 2022 · Filed December 20, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 35,546 |
Reported balance
After 2022-12-16 transaction · row 1
1 source rowRow 1 · 2022-12-16 · Sale · Disposed 19,688 · Balance 35,546 F1: Shares sold pursuant to a Rule 10b5-1 sales plan, entered into on December 6, 2021 and amended and restated on October 24, 2022, to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a Rule 10b5-1 sales plan, entered into on December 6, 2021 and amended and restated on October 24, 2022, to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2022 Filed Dec 20, 2022 20:01 UTC | TAO Synergies Inc. SNPX · Entity 7482 | SaleCommon Stock, par value $0.0001 per share | 19,688 | $1.17 | $23,072.37 |
DisclosureSEC source: 0001104659-22-128768 · tm2233089-3_4seq1.xml · nonDerivative · entry 1 Alkon Daniel L. · CIK 0001686138 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,546 F1 · shares: Shares sold pursuant to a Rule 10b5-1 sales plan, entered into on December 6, 2021 and amended and restated on October 24, 2022, to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 16:02 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 112,000 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001104659-22-119879 · tm2230820-4_4seq1.xml · derivative · entry 1 Alkon Daniel L. · CIK 0001686138 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock, par value $0.0001 per share · 112,000 shares Expires 2032-11-15 F1 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer. Read SEC document |
| November 15, 2022 Filed Dec 1, 2022 19:49 UTC Amendment | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001104659-22-123800 · tm2231816-3_4aseq1.xml · derivative · entry 1 Alkon Daniel L. · CIK 0001686138 · Director · See Remark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock, par value $0.0001 per share · 75,000 shares Expires 2032-11-15 F1 · shares: This filing amends the Form 4, filed on November 17, 2022 by Mr. Alkon to reflect the lower number of options allowed to be granted pursuant to the per-participant grant limit contained in the Issuer's 2020 Equity Incentive Plan, as amended. F2 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 18:05 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantCommon Stock, par value $0.0001 per share | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-092713 · tm2122331-2_4seq1.xml · nonDerivative · entry 1 Alkon Daniel L. · CIK 0001686138 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,484 F1 · balance_after: Includes 80,000 restricted stock units granted on July 13, 2021 (the "Grant Date") under the Issuer's 2020 Equity Incentive Plan which will vest 50% on the six month anniversary of the Grant Date and the remaining 50% on the one year anniversary of the Grant Date. Read SEC document |
| July 13, 2021 Filed Dec 1, 2022 19:53 UTC Amendment | TAO Synergies Inc. SNPX · Entity 7482 | GrantCommon Stock, par value $0.0001 per share | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-123807 · tm2231816-7_4aseq1.xml · nonDerivative · entry 1 Alkon Daniel L. · CIK 0001686138 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,234 F1 · shares: This filing amends the Form 4, filed on July 15, 2021 by Mr. Alkon to reflect the lower number of options allowed to be granted pursuant to the per-participant grant limit contained in the Issuer's 2020 Equity Incentive Plan, as amended. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 13:01 UTC | TAO Synergies Inc. SNPX · Entity 7482 | PurchaseCommon Stock, par value $0.0001 per share | 10,000 | $8.26 | $82,600.00 |
DisclosureSEC source: 0001104659-21-081898 · tm2119874d2_4.xml · nonDerivative · entry 1 Alkon Daniel L. · CIK 0001686138 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,484 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.19 to $8.35, inclusive. The reporting person undertakes to provide to Synaptogenix, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 40,000 | Not disclosed Strike: $0.97 | Not disclosed |
DisclosureSEC source: 0001104659-20-132155 · tm2037705d7_4seq1.xml · derivative · entry 6 Alkon Daniel L. · CIK 0001686138 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 150,000 | Not disclosed Strike: $3.93 | Not disclosed |
DisclosureSEC source: 0001104659-20-132155 · tm2037705d7_4seq1.xml · derivative · entry 5 Alkon Daniel L. · CIK 0001686138 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 167,000 | Not disclosed Strike: $19.62 | Not disclosed |
DisclosureSEC source: 0001104659-20-132155 · tm2037705d7_4seq1.xml · derivative · entry 4 Alkon Daniel L. · CIK 0001686138 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 167,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 124,274 | Not disclosed Strike: $10.56 | Not disclosed |
DisclosureSEC source: 0001104659-20-132155 · tm2037705d7_4seq1.xml · derivative · entry 3 Alkon Daniel L. · CIK 0001686138 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 124,274 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 5,469 | Not disclosed Strike: $56.00 | Not disclosed |
DisclosureSEC source: 0001104659-20-132155 · tm2037705d7_4seq1.xml · derivative · entry 2 Alkon Daniel L. · CIK 0001686138 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,469 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerCommon Stock | 29,688 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-132155 · tm2037705d7_4seq1.xml · nonDerivative · entry 1 Alkon Daniel L. · CIK 0001686138 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held. Read SEC document |
| November 24, 2020 Filed Nov 27, 2020 17:09 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001104659-20-130080 · tm2037145d7_4seq1.xml · derivative · entry 1 Alkon Daniel L. · CIK 0001686138 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-11-24 F1 · derivative.exercise_date: The shares will immediately vest and become exercisable subject to and upon consummation of (1) the merger of PM Merger Sub 1, LLC with and into Metuchen Pharmaceuticals, LLC ("Metuchen"), with Metuchen surviving as a wholly-owned subsidiary of Petros Pharmaceuticals, Inc. ("Petros") and (2) the merger of PN Merger Sub 2, Inc. with and into Neurotrope, Inc. ("Neurotrope"), with Neurotrope surviving as a wholly-owned subsidiary of Petros. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 18:01 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0001144204-19-002683 · tv511523_4.xml · derivative · entry 1 Alkon Daniel L. · CIK 0001686138 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-01-22 F1 · derivative.exercise_date: The stock option award was made pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. The stock options shall vest according to the following schedule: 50% vest on the date of grant, with the remaining stock options vesting in equal quarterly installments over a two-year period following the date of grant. Read SEC document |
| April 11, 2017 Filed Apr 13, 2017 21:46 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 167,000 | $0.00 Strike: $19.62 | $0.00 |
DisclosureSEC source: 0001144204-17-020447 · v464203_4.xml · derivative · entry 1 Alkon Daniel L. · CIK 0001686138 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,000 Underlying: Common Stock · 167,000 shares Expires 2027-04-11 F1 · security: Such option grant is subject to stockholder approval of the Issuer's 2017 Equity Incentive Plan under which the option was granted. F2 · derivative.exercise_date: The stock options vest in equal quarterly installments over a three-year period. Read SEC document |
| November 21, 2016 Filed Nov 23, 2016 17:01 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option · Derivative | 3,976,767 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001144204-16-136403 · v453758_4.xml · derivative · entry 1 Alkon Daniel L. · CIK 0001686138 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,976,767 Underlying: Common Stock · 3,976,767 shares Expires 2026-11-21 F2 · price: These options were granted in connection with the Issuer's grant to certain officers, directors and employees following the final closing of a private placement on November 21, 2016. F1 · derivative.exercise_date: One half of the stock options vest immediately upon grant and the remaining one half vest in equal daily installments over a four-year period beginning on the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.